|
Real-time Estimate
Cboe BZX
21:10:56 21/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 7.065 USD | +3.14% |
|
+8.24% | -10.93% |
| 08-11 | DiaMedica Therapeutics Inc., Q2 2026 Earnings Call, Aug 11, 2026 | |
| 08-11 | DiaMedica Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: DiaMedica Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 124.8 | 56.55 | 142.3 | 334.1 | 568.4 | 517.5 | - | - |
| Change | - | -54.69% | 151.72% | 134.69% | 70.13% | -8.96% | - | - |
| Enterprise Value (EV) | 124.8 | 56.55 | 142.3 | 334.1 | 568.4 | 517.5 | 517.5 | 517.5 |
| Change | - | -54.69% | 151.72% | 134.69% | 70.13% | -8.96% | 0% | 0% |
| P/E | -5.74x | -3.04x | -4.73x | -9.05x | -11.4x | -8.43x | -8.48x | -6.74x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.2x | -0.3x | - | -0.7x | -0.5x | 15.31x | -0.3x |
| Capitalization / Revenue | - | - | - | - | - | - | - | 80.6x |
| EV / Revenue | - | - | - | - | - | - | - | 80.6x |
| EV / EBITDA | - | - | -0x | -0x | -0x | -8.42x | -7.79x | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -8.04x | -7.17x | -4.92x |
| EV / FCF | - | - | - | -0x | -0x | -8.39x | -7.66x | -5.64x |
| FCF Yield | - | - | - | -9.45% | -7.15% | -11.9% | -13.1% | -17.7% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.65 | -0.52 | -0.6 | -0.6 | -0.7 | -0.8125 | -0.808 | -1.017 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | 6.42 |
| EBITDA 1 | - | - | -28.81 | -38.06 | -47.83 | -61.43 | -66.45 | - |
| EBIT 1 | -17.41 | -19.07 | -28.85 | -38.12 | -47.89 | -64.35 | -72.17 | -105.1 |
| Net income 1 | -17.34 | -18.63 | -26.3 | -34.92 | -45.62 | -62.66 | -71.07 | -103.9 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 3.730 | 1.580 | 2.840 | 5.430 | 7.960 | 6.850 | 6.850 | 6.850 |
| Nbr of stocks (in thousands) | 26,439 | 26,443 | 37,954 | 42,761 | 52,077 | 53,926 | - | - |
| Announcement Date | 14/03/22 | 28/03/23 | 19/03/24 | 17/03/25 | 30/03/26 | - | - | - |
1CAD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.43x | - | - | - | 369M | |
| 20.78x | 7.3x | 14.73x | 1.43% | 70.88B | |
| 48.85x | 9.38x | 29.23x | 0.04% | 62.49B | |
| 30.44x | 6.47x | 16.8x | -.--% | 26.34B | |
| -73.25x | 14.16x | -68.28x | -.--% | 26.21B | |
| -14.7x | 5.35x | -6.73x | -.--% | 24.13B | |
| 28.25x | 5.33x | 17.72x | -.--% | 20.72B | |
| 45.45x | 16.69x | 33.86x | 0.33% | 15.69B | |
| 18.03x | 5.37x | 12.55x | -.--% | 14.46B | |
| -15.41x | 3481.82x | -17.8x | -.--% | 14.24B | |
| Average | 8.00x | 394.65x | 3.56x | 0.2% | 27.55B | |
| Weighted average by Cap. | 15.93x | 188.28x | 7.95x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- DMAC Stock
- Valuation DiaMedica Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
